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Background: Currently, a new generation of synthetic pulmonary surfactants is being developed 
that may eventually replace animal-derived surfactants used in the treatment of respiratory distress 
syndrome. Enlightened by this, we prepared a synthetic peptide-containing surfactant  (Synsurf) 
consisting of phospholipids and poly-l-lysine electrostatically bonded to poly-l-glutamic acid. 
Our objective in this study was to investigate if bronchoalveolar lavage (BAL)-induced acute 
lung injury and surfactant deficiency with accompanying hypoxemia and increased alveolar and 
physiological dead space is restored to its prelavage condition by surfactant replacement with 
Synsurf, a generic prepared Exosurf, and a generic Exosurf containing Ca2+.
Methods: Twelve adult New Zealand white rabbits receiving conventional mechanical ventila-
tion underwent repeated BAL to create acute lung injury and surfactant-deficient lung disease. 
Synthetic surfactants were then administered and their effects assessed at specified time points 
over 5 hours. The variables assessed before and after lavage and surfactant treatment included 
alveolar and physiological dead space, dead space/tidal volume ratio, arterial end-tidal carbon 
dioxide tension (PCO
2
) difference (mainstream capnography), arterial blood gas analysis, 
calculated shunt, and oxygen ratios.
Results: BAL led to acute lung injury characterized by an increasing arterial PCO
2
 and a 
simultaneous increase of alveolar and physiological dead space/tidal volume ratio with no 
intergroup differences. Arterial end-tidal PCO
2
 and dead space/tidal volume ratio correlated 
in the Synsurf, generic Exosurf and generic Exosurf containing Ca2+ groups. A significant and 
sustained improvement in systemic oxygenation occurred from time point 180 minutes onward 
in animals treated with Synsurf compared to the other two groups (P , 0.001). A statistically 
significant decrease in pulmonary shunt (P , 0.001) was found for the Synsurf-treated group 
of animals, as well as radiographic improvement in three out of four animals in that group.
Conclusion: In general, surfactant-replacement therapy in the animals did not fully restore the 
lung to its prelavage condition. However, our data show that the formulated surfactant Synsurf 
improves oxygenation by lowering pulmonary shunt.
Keywords: pulmonary surfactant, synthetic peptides, respiratory dead space, capnometry, 
pulmonary gas exchange, oxygenation
Introduction
Surfactant-replacement therapy with animal-derived surfactant preparations is an 
established treatment modality for respiratory distress syndrome that revolution-
ized the care of preterm babies in intensive care units.1,2 Pulmonary surfactant 
is a complex mixture of phospholipids and at least four apoproteins that reduces 
surface tension at the alveolar surface.3 The mixture has unique spreading proper-
ties, promotes lung expansion during inspiration, and prevents lung collapse during 
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expiration. Of all the protein components in the mixture, 
the  hydrophobic  surfactant proteins B (SP-B) and C (SP-C) 
have an essential function in the spreading, adsorption, and 
stability of surfactant lipids.4–6
Over the past decade, natural and synthetic surfactants 
have extensively been tested with regard to their in vitro 
properties and in vivo physiologic effects.1 Unfortunately, 
synthetic products have lost popularity in favor of natural 
products that contain low concentrations of SP-B and SP-C, 
which are essential for adsorption and spreading of the surfac-
tant film at the air–liquid interface. However, commercially 
the large-scale production and supply of natural surfactants 
are not only time-consuming and expensive with a limited 
supply, but there are concerns about the reproducibility 
and purity and the possibility of transmission of infectious 
 material.7 The development of an effective artificial surfac-
tant mixture, devoid of foreign protein, that can be prepared 
in large quantities at a reasonable cost remains challenging. 
Moreover, a common denominator in acute lung diseases is 
inactivation of surfactant by plasma and other components. 
Much work is therefore aimed at constructing a new gen-
eration of synthetic surfactants that will be more resistant 
towards inactivation.
Various research groups have chemically prepared 
peptides with amino acid sequences based on that of SP-B. 
In two such studies, the treatment of preterm infant rhesus 
monkeys and human infants with respiratory distress syn-
drome was demonstrated with a peptide/phospholipid mixture 
(KL
4
-surfactant).8,9 In both studies, this synthetic surfactant 
expanded the pulmonary alveoli and promoted gas exchange. 
Based on such a design, we prepared a surfactant consisting of 
the phospholipids dipalmitoylphosphatidylcholine (DPPC), 
phosphatidylglycerol (PG), and two polymers: poly-l-lysine 
electrostatically complexed with poly-l-glutamic acid (Syn-
surf [S]). The polymers were added to the phospholipids, in 
order to mimic the hydrophobic and hydrophilic nature of 
SP-B in the mixture.
In this study, we were particularly interested to compare 
the efficacy of S as a synthetic surfactant in a comparative 
study with a previously used synthetic protein-free surfac-
tant, Exosurf Neonatal10,11 (we prepared a generic version), 
hereafter named GE. Although similar in chemical compo-
sition, we cannot guarantee that the GE used in our experi-
ments was identical to commercially manufactured Exosurf 
Neonatal, as it was discontinued at the time of the present 
study.  However, in a previous study12 before its discontinua-
tion, we were able to compare the in vivo efficacy of our GE 
and its physiological effects and gas-exchange  capabilities 
with the then-available commercial Exosurf Neonatal 
product. Although we found differences that we could not 
provide plausible explanations for in the on-site formulations, 
the overall outcome in performance was similar to Exosurf 
Neonatal. Moreover, the surface tension-lowering ability of 
the GE preparations were not significantly different to that 
of Exosurf Neonatal when we tested them.13 In the present 
study, we also found that the surface-lowering ability of GE 
and S is virtually similar. Although surface-tension measure-
ments strongly depend on the technique applied, our data, 
measured under dynamic conditions, are in agreement with 
the less effective surface tension-lowering ability reported 
by others in the absence of SP-B and SP-C.14
Considering reports in literature15,16 that bivalent cations 
such as Ca2+ can increase the speed of surface adsorption of 
surfactant molecules and to stabilize films in experimental 
conditions, we decided to include a GE preparation mixed 
with Ca2+ (GE
Ca
2+) to elucidate the beneficial effect. Hence 
we tested the efficacy of three surfactant preparations in 
an adult rabbit model with acute lung injury and surfac-
tant deficiency. We tested the hypothesis that a synthetic 
peptide-containing surfactant (S) would improve systemic 
oxygenation and restore the surfactant-deficient lungs to 
prelavage condition after surfactant depletion was induced 
by repeated bronchoalveolar lavage (BAL) in comparison to 
two synthetic surfactants devoid of protein.
Materials and methods
DPPC was obtained from Avanti Polar Lipids (Alabaster, AL, 
USA). PG, cetyl alcohol, tyloxapol, poly-l-lysine (molecular 
weight 16.1 kDa) and poly-l-glutamic acid (molecular 
weight 12 kDa) were purchased from Sigma-Aldrich 
(St Louis, MO, USA). Phospholipid purity was verified by 
thin-layer chromatography.17 Sterile water for injection was 
used in the preparation of surfactant. Chloroform used was 
high-performance liquid chromatography-grade (Merck, 
 Darmstadt, Germany).
Experimental surfactant preparations
Synsurf (S) was prepared by mixing DPPC, hexadecanol, 
and PG in a 10:1.1:1 ratio (w/w) in chloroform. The organic 
solvent was then removed by rotary evaporation and the 
mixture was dried under a continuous stream of nitrogen at 
room temperature. Poly-l-lysine (∼100–120 residues) was 
mixed with poly-l-glutamate (approximately 80 residues) 
and incubated at 37°C in 0.1 M NaCl to give a complex that 
was 50% neutralized. The complex was prepared in such a 
manner as to be positively charged through having an excess 
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of poly-l-lysine residues. The dried phospholipid film was 
then hydrated with the polymer mixture (3% by weight of 
the phospholipid concentration) and gently mixed in the 
presence of glass beads. A Branson (Danbury, CT, USA) 
B-15P ultrasonicater fitted with a microtip was then used 
to sonicate the mixture on ice under a stream of nitrogen 
(power of 20 watts for 7 × 13 seconds; 60-second intervals). 
Hereafter, 24 mg of tyloxapol was added to the prepara-
tion, and the tube was sealed under nitrogen before use. 
The GE surfactant was also prepared in a similar fashion as 
described above and consisted of three components: DPPC/
hexadecanol/tyloxapol (13.5:1.5:1) in 0.1 M NaCl. The dose 
of S, GE, and GE
Ca
2+ used was 100 mg/kg. CaCl
2
 included in 
GE
Ca
2+ amounted to 5 mM.
Animal preparation
Animal care and experimental procedures were performed 
under approval from the Faculty of Health Sciences Research 
Committee of Stellenbosch University. Adult New Zealand 
white rabbits weighing 2.5–3.75 kg ± 0.39 kg were premedi-
cated with ketamine (25–50 mg/kg). They were positioned on 
their back and kept in this position throughout the experiment. 
An auricular intravenous line was inserted, and an infusion 
(5 mL/kg/hour) with a Ringer’s glucose solution started. 
 Animals then underwent tracheostomy, and an uncuffed endo-
tracheal tube (size 2.5–4.0 mm) was inserted and firmly tied 
to exclude air leaks. Intravenous pentobarbital (6 mg/kg body 
weight) and pancuronium bromide (0.1 mg/kg body weight) 
were administered. Anesthesia was maintained with an infusion 
of sodium pentobarbital at a dose of 6 mg/kg/hour. The left 
carotid artery was catheterized for arterial blood gas measure-
ments and hemodynamic monitoring (blood pressure and pulse 
rate). Lidocaine (1%) was used for local anesthesia at surgical 
sites. Animals were ventilated using the time-cycled pressure-
limited mode (Julian Anaesthetic Workstation; Dräger, Lübeck, 
Germany) at a peak inspiratory pressure necessary to maintain 
a tidal volume (V
T
) of 10 mL/kg and partial pressure of car-
bon dioxide in arterial blood (PaCO
2
) between 4 and 7.5 kPa 
(30–56 mmHg). The V
T
 of a spontaneously breathing young 
adult rabbit (2.775 ± 0.198 kg) varies between 19 and 25 mL, 
and the mean PaCO
2
 for rabbits weighing 2.9–3.5 kg (in the 
absence of ketamine) is 31.8 ± 1.7 mmHg (4.2 ± 0.22 kPa).18,19 
Using the same model, V
T
 varying between 8 and 12 mL/kg 
resulting in partial arterial pressure of CO
2
 between 4.5 and 
5.3 kPa have been reported.20–22 However, since a body of 
researchers used V
T
 of 10 mL/kg in adult rabbits, we decided 
to standardize our protocol accordingly.23–27 This V
T
 was 
verified by a combined neonatal CO
2
/flow sensor (CO
2
SMO 
plus respiratory profile monitor model 8000; Novametrix 
Medical Systems, Wallingford, CT, USA). At the moment of 
the incision of the trachea, continuous intravenous infusion 
of pentobarbital sodium was commenced (6 mg/kg/hour). 
Neuromuscular paralysis was achieved by administering 
intravenous pancuronium bromide (0.1 mg/kg) on an hourly 
basis. The rectal temperature was monitored, and the aim was 
to keep it between 38°C and 40°C with an electrical heating 
pad. The reported normal range of rectal temperatures in the 
rabbit is 38.6°C–40.1°C.19 The blood pressure transducer was 
intermittently flushed with saline containing heparin 5 IU 
heparin/mL. The blood pressure of the healthy rabbit varies 
between 90–130 (systolic) and 60–91 (diastolic) mmHg.19 The 
depth of anesthesia was intermittently checked by pinching 
the web of a hind-leg paw to create a painful stimulus, and by 
the flow sensor to check for spontaneous breathing efforts. 
The study lasted 5 hours before the animals were killed by 
a lethal intra-arterial injection of 15% potassium chloride.
Bronchoalveolar lavage and surfactant 
treatment
Animals were subjected to repeated warm saline (37°C) 
lavage (20 mL/kg) via the endotracheal tube, similar to 
the technique described by Lachmann et al.28 Lavage end 
points included a decrease in arterial oxygen tension (PaO
2
) 
to below 11 kPa (fraction of inspiratory oxygen [FiO
2
] 1.0) 
and a decrease in dynamic respiratory compliance (C
dyn
) by 
40% or more. The total volume of lavage fluid (corrected 
for body weight) necessary to achieve significant surfactant 
deficiency/acute lung injury was recorded together with the 
volume retrieved. The retrieved volume was expressed as a 
percentage of the instilled volume. A 10-minute period was 
allowed for stabilization following lavage, and then animals 
were randomized into three treatment groups. Group A 
received the GE protein-free surfactant, group B the GE plus 
Ca2+ (5 mM), and group C the peptide-containing surfactant 
(Synsurf, InnovUS, Stellenbosch University) via the endo-
tracheal tube (DPPC concentration 100 mg/kg).
Measurement of lung mechanics, 
capnometry, and arterial blood gases
The FiO
2
 (1.0), V
T
 (aim 10 mL/kg), respiratory rate (40 breaths 
per minute, spontaneous breathing rate of a rabbit varies 
between 32 and 60/minute), positive end-expiratory pres-
sure (PEEP: 5 cmH
2
O after lavage), and the inspiratory time 
(T
I
):expiratory time (T
E
) at 1:1.5 (T
I
 0.6 seconds, T
E
 0.9 sec-
onds) were kept constant throughout the study.  Arterial blood 
gases (Radiometer ABL 500 blood gas  analyzer; Regent 
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Medic, London, UK), pulmonary functions (dynamic expiratory 
airway resistance [Raw
e
], V
T
, C
dyn
), ventilator settings, physio-
logical parameters (rectal temperature, blood pressure, pulse 
rate), oxygenation, capnometry, and other calculations were 
recorded/measured before and after lavage and at 15, 30, 
60, 90, 120, 180, 240, and 300 minutes after surfactant-
replacement therapy. Oxygenation variables were calculated. 
The arterial/alveolar (a/A) ratio = PaO
2
/(P
B
 - 47) FiO
2
 - 
PaCO
2
/R (R assumed respiratory quotient 0.8).  Pulmonary 
function and CO
2
 measurements were measured with the 
CO
2
SMO Plus respiratory profile monitor. The low dead-
space measurement chamber with flow sensor was placed 
inbetween the ventilator circuit wye and endotracheal tube 
adaptor. The CO
2
SMO Plus monitor measures and displays 
respiratory mechanics and carbon dioxide data and calculates 
flow, CO
2
, and oximetry-related parameters. Flow-sensor 
calibration was not necessary, since the device automati-
cally zeroed periodically by internal values. Partial pressure 
of end-tidal carbon dioxide tension (PET
CO2
) was measured 
by mainstream infrared absorption. By using the tension of 
carbon dioxide (PCO
2
)
 
and volume measurements, the ana-
tomic dead space, alveolar dead space (V
Dalv
), physiological 
dead space, physiological dead space/V
T
 ratio, and V
Dalv
/V
T
 
ratio were determined. The arterial end-tidal PCO
2
 difference 
(P[a-et]CO
2
) was obtained by subtracting the PetCO
2
 from 
PaCO
2
 of an arterial blood gas sample. The shunt was calcu-
lated as follows: Q
s
/Q
t
 = 88.77 - 2.4 (20.4 log PaO
2
/FiO
2
).29
Chest radiography
Anteroposterior chest radiographs were taken prior to lavage, 
immediately prior to randomization, and at the end of the 
study. The distance between the probe and film was kept 
at 24 cm. Changes in lung fields were assessed in a blinded 
manner in regard to whether the radiographic opacification 
following lavage (atelectasis) resolved (better), remained 
unchanged (similar), or deteriorated (worse).
Statistical methods
One-way analysis of variance and linear mixed-effects mod-
eling were used as described by Pinheiro et al30 and Maritz 
et al.31 Variables measured for groups at the predetermined 
time points were also compared using unpaired t-tests. For 
continuous variables measured over time, a linear regres-
sion of the variables over time by least-squares analysis 
was used to compare groups by differences in the initial 
responses to surfactant (y-intercepts) and change over time 
(slopes). Data are expressed as means ± standard deviation. 
A P-value , 0.05 was taken as significant (Statistica version 10; 
StatSoft, Tulsa, OK, USA). GraphPad (La Jolla, CA, USA) 
Prism 5 was used to determine correlations.
Results
Baseline characteristics
The mean (± standard deviation) values for weight and 
prelavage mean arterial blood pressure, arterial blood gases, 
capnometry, and pulmonary functions are shown in Table 1. 
The total volume of lavage fluid required to induce acute 
Table 1 results before bronchoalveolar lavage at 3 hours and 
5 hours after surfactant treatment in twelve rabbits
Variable Synsurf group  
(n = 4)
Exosurf group  
(n = 4)
Exosurf + Ca2+ 
group (n = 4)
Weight (kg) 3.13 ± 0.56 2.95 ± 0.19 3.44 ± 0.24
Pre-VT (mL/kg)
180 minutes
300 minutes
10.08 ± 0.29
10.08 ± 0.17
10.05 ± 0.10
10.20 ± 0.58
9.85 ± 0.21
9.75 ± 0.24
10.03 ± 0.35
10.13 ± 0.19
9.93 ± 0.22
Pre-MABP  
(mmHg)
180 minutes
300 minutes
82.60 ± 4.07
89.50 ± 11.21
87.00 ± 15.12
92.40 ± 3.83
100.30 ± 6.99
96.75 ± 12.2
91.50 ± 7.51
93.25 ± 4.72
91.00 ± 14.67
Pre-PaO2  
(mmHg)
Post-
180 minutes
300 minutes
499.70 ± 9.46
57.95 ± 14.90
152.30 ± 49.27
281.30 ± 47.64
511.10 ± 17.38
53.25 ± 15.97
85.69 ± 25.85
74.25 ± 8.84
509.30 ± 24.08
50.81 ± 18.30
109.90 ± 46.32
85.69 ± 32.56
Pre-a/A ratio
Post-
180 minutes
300 minutes
0.76 ± 0.02
0.09 ± 0.02
0.23 ± 0.07
0.42 ± 0.07
0.77 ± 0.04
0.08 ± 0.02
0.13 ± 0.04
0.11 ± 0.01
0.76 ± 0.03
0.08 ± 0.03
0.16 ± 0.07
0.13 ± 0.05
Pre-PaCO2  
(mmHg)
180 minutes
300 minutes
40.69 ± 3.15
38.44 ± 4.99
36.75 ± 2.12
39.38 ± 6.26
38.63 ± 5.49
40.13 ± 4.18
36.19 ± 8.04
36.19 ± 4.99
38.81 ± 7.15
Pre-PetCO2  
(mmHg)
180 minutes
300 minutes
14.25 ± 3.06
9.56 ± 1.88
9.75 ± 1.50
14.63 ± 3.09
10.13 ± 2.17
9.38 ± 1.44
13.88 ± 1.3
10.69 ± 0.94
9.75 ± 2.21
Pre-P(a-et)CO2  
(mmHg)
Postlavage
300 minutes
26.44 ± 4.95
43.50 ± 15.16
27.00 ± 2.60
24.75 ± 6.15
42.66 ± 8.67
30.75 ± 3.06
22. 31 ± 7.07
42.88 ± 15.07
29.06 ± 8.58
Cdyn (mL/cm  
H2O/kg)
Prelavage
Postlavage
300 minutes
0.93 ± 0.16
0.47 ± 0.04
0.47 ± 0.01
0.98 ± 0.16
0.46 ± 0.05
0.42 ± 0.02
0.88 ± 0.17
0.42 ± 0.06
0.44 ± 0.06
rawe
Prelavage
Postlavage
300 minutes
33.75 ± 3.59
53.50 ± 4.20
46.75 ± 11.33
45.25 ± 24.06
74.25 ± 25.93
72.00 ± 22.32
36.75 ± 11.03
59.25 ± 13.07
55.25 ± 9.85
Note: Data are shown as the means ± standard deviation.
Abbreviations: VT, tidal volume; MABP, mean arterial blood pressure; PaO2, arterial 
PO2; PAO2, alveolar PO2; PaCO2, arterial PCO2; PetCO2, end-tidal PCO2; P(a-et)
CO2, arterial end-tidal PCO2; rawe, expiratory airway resistance; Cdyn, dynamic 
respiratory compliance; a/A ratio, arterial/alveolar ratio.
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Figure 2 Time profile of pulmonary shunt after administration of surfactant in 
rabbit groups.
lung injury and surfactant deficiency (S 74.75 ± 17.04 mL, 
GE 73.58 ± 21.2 mL, GE
Ca
2+ 73.58 ± 21.2 mL) and the 
percentage of fluid retrieved from the airways (lavage 
%: S 86.5% ± 6.73%; GE 79.38% ± 7.70%; GE
ca
2+ 
79.25% ± 3.30%) did not differ between the groups. The end 
points of lavage were similar between the groups. Although 
the aim was to randomize the individual animals 10 minutes 
after the final lavage and after the chest X-ray was performed, 
in reality, the randomization occurred at 9 ± 3.16 minutes. 
There were no intergroup differences.
Changes in gas exchange and shunt
The changes in PaO
2
 and a/A ratio before and after surfac-
tant treatment are given in Table 1. The PaO
2
 and a/A ratio 
decreased significantly (P , 0.05) after lavage. Following 
treatment with the respective surfactants, the following 
was noted: oxygenation as reflected by the PaO
2
 and a/A 
ratio improved significantly over time in comparison to the 
postlavage level (time point 0, P , 0.05; Figure 1, A and B). 
However, significantly better and sustained improvement in 
systemic oxygenation occurred from baseline at 60 min-
utes in the animals treated with S (P = 0.02) compared 
to the other two groups (global test mixed-effects model 
χ2 = 58.81, P , 0.001). Improvement in oxygenation was 
also recorded for the animals treated with GE
Ca
2+, but it was 
significantly less than that recorded in the S group. A statis-
tically significant decrease in calculated pulmonary shunt 
(time period 0–300 minutes) was observed in the S-treated 
group of animals (intergroup differences S 31.49 ± 10.68 vs 
GE 41.13 ± 1.63, P = 0.01, and S vs GE
Ca
2+ 37.36 ± 5.29, 
P = 0.002; Friedman analysis of variance). At 300 minutes, 
the mean calculated value for S was 12.03% versus 32.17% 
and 40.33% for GE
Ca
2+ and GE, respectively (Figure 2).
Changes in pulmonary mechanics
Despite the significant improvement in systemic oxygenation 
(gas exchange), no real changes in pulmonary mechanics 
from baseline (time point 0) over time were demonstrated. 
C
dyn
 decreased significantly from the prelavage value, and 
in spite of surfactant treatment decreased nonsignificantly 
thereafter over time in the three groups (Figure 3). BAL 
resulted in significant reduction of C
dyn
 in all of the rabbits and 
an increase of Raw
e
 by approximately 52%, 64% and 61%, 
respectively, from baseline (Table 1). After surfactant instil-
lation, no significant changes for these two parameters were 
observed over time. Capnometry revealed the effects of lavage 
on dead spaces and the changes in V
Dalv
/V
T
 ratio, physiological 
dead space/V
T
 ratio, V
DPhys
/V
T
 ratio and the arterial end-tidal 
0
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Figure 1 Time profile for oxygenation in the rabbit groups, as reflected by the 
arterial PaO2 and a/A ratio after surfactant administration.
Abbreviations: a/A, arterial/alveolar; PaO2, arterial PO2. 
PCO
2
  difference P(a-et)CO
2
 before lavage and after surfactant 
treatment (Table 1 and Figure 4A–C). At randomization 
(baseline), all of these variables had significantly changed 
in comparison to the prelavage  measurements. In all three 
groups, the V
D
/V
T
 ratio as well as the V
Dalv
/V
T
 ratio did not 
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change significantly from baseline, despite treatment with 
surfactant. This finding, together with the increased P(a-et)
CO
2
, indicates a ventilation–perfusion mismatch.
Correlations
We found that the best correlation could be calculated 
between the physiologic dead space and the a/A PO
2
 ratio, 
as well as the physiologic dead space/V
T
 ratio and a/A PO
2
 
ratio in all three groups of rabbits (Table 2). We also found 
good correlations between the arterial end-tidal PCO
2
 and 
V
Dalv
, as well as V
Dalv
/V
T
 components in the S- and GE
Ca
2+-
treated groups of rabbits (Table 3). There was a significant 
negative correlation between P(a-et)CO
2
 and PaO
2
 in S- and 
GEca2+-treated rabbits (S, r = -0.65, P = 0.044; GE
Ca
2+, 
r = -0.74, P = 0.014) and a significant positive correlation 
between P(a-et)CO
2
 and Q
s
/Q
t
 in all three groups for shunt 
percentage above 30% (S, r = 0.86, P = 0.0014; GE, r = 0.92, 
P = 0.0002; GE
Ca
2+, r = 0.91, P = 0.0003).
radiographic changes
Radiographic improvement was found in three out of four 
animals treated with S, in comparison to one out of four 
rabbits in the GE
Ca
2+ group and two out of four in the pure 
GE-treated rabbit group.
Discussion and conclusions
By selecting the well-established saline-lavage methodology 
introduced by Lachmann et al,28 we were able to create acute 
respiratory failure and lung injury with associated surfactant 
deficiency in adult rabbits. Repeated saline lavage brought 
about a deterioration in gas exchange, increased dead spaces, 
0.4
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Figure 3 Compliance of the respiratory system: time-profile comparison of rabbit 
groups prelavage and after surfactant administration.
Abbreviation: Cdyn, dynamic respiratory compliance.
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Figure 4 Time profile of (A) alveolar dead space/tidal volume ratio (VDalv/VT), 
(B) dead space/tidal volume ratio (VD/VT), and (C) arterial end-tidal PCO2 difference 
before and after surfactant administration.
Table 2 relation between arterial/alveolar PO2 ratio and dead-
space components
Surfactant  
group
Variable Correlation coefficients
r r2 P
Synsurf VDalv 0.37 0.13 0.2704
VDalv/VT 0.31 0.10 0.3510
VDphys 0.94 0.88 0.0000
VDphys/VT 0.90 0.80 0.0001
Exosurf VDalv 0.49 0.24 0.0928
VDalv/VT 0.31 0.10 0.2675
VDphys 0.93 0.86 0.0000
VDphys/VT 0.93 0.86 0.0000
Exosurf + Ca2+ VDalv 0.60 0.36 0.0497
VDalv/VT 0.58 0.33 0.0307
VDphys 0.85 0.72 0.0006
VDphys/VT 0.83 0.69 0.0009
Abbreviations: VDalv, alveolar dead space; VDalv/VT, alveolar dead-space/tidal volume 
ratio; VDphys, physiologic dead space; VDphys/VT, physiologic dead space/tidal volume 
ratio.
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intrapulmonary right-to-left shunting, venous admixture, and 
impaired lung mechanics.29,32,33
Following lavage, alveoli become unstable and tend to 
collapse abruptly during expiration when the transalveolar 
pressure decreases below critical closing pressure.34 In the 
presence of continuing capillary perfusion of these unstable 
gas-exchange units, venous admixture (intrapulmonary 
shunt) increases. Surfactant deficiency induced by BAL 
elevates alveolar and physiological dead space,25 lowers 
mean lung volume above residual volume,35 decreases arte-
rial PaO
2
, increases arterial PaCO
2
, decreases the a/A ratio, 
elevates pulmonary arterial pressure,36 elevates systolic right 
ventricular pressure,23 increases right-to-left shunting/venous 
admixture,23,25 and increases perfusion of low ventilation–
perfusion regions.37 In the adult rabbit, whole-lung lavage 
increases V
Dalv
 almost fivefold and the V
Dalv
/V
T
 ratio from 
zero to one-third of V
T
.25 If not treated with surfactant, the 
majority of lavaged rabbits deteriorate over 1–2 hours in 
regard to static lung compliance and oxygenation status.38 
Like others, we found that lavage increased the alveolar and 
physiologic dead space/V
T
 ratio.25 The increase in physiologi-
cal dead space would indicate that less of the tidal volume 
is involved in gas exchange. In addition we found a good 
correlation between alveolar and physiological dead space/
V
T
 ratio and arterial end-tidal PCO
2
 differences for the S 
and GE
Ca
+2 groups, but not for the GE group (Table 3). In 
general, higher arterial end-tidal differences were based on 
an increase in dead space/V
T
 ratio. The alveolar dead space/
V
T
 ratio has previously been shown to be the best indicator 
of ventilation disorders and to indicate right-to-left shunt, 
based mainly on atelectasis.25 Regions of high ventilation–
perfusion ratios contribute to dead space, and the P(a-A)CO
2
 
value is accepted as an indicator of high ventilation–perfusion 
lung regions.39 Within 3 hours following surfactant instil-
lation, we found a significant and sustained improvement 
in oxygenation in S-treated animals compared to the other 
groups. Concurrent with the improved oxygenation status, 
we observed a significant decrease in the P(a-et)CO
2
 in the 
S and GE
Ca
2+ groups, which led us to conclude that S clearly 
improved (decreased) high ventilation–perfusion regions, 
more so than was the case in the other two groups.39
An increase in oxygenation following instillation of 
surfactant is largely due to an increase in lung volume, more 
specifically the functional residual capacity (FRC),40,41 and it 
is reasoned that the increase in FRC is due to stabilization of 
already open but underventilated air spaces and recruitment 
of atelectatic gas-exchange units. In the presence of sur-
factant, the relative contribution of these two mechanisms 
may depend on ventilator settings, ie, employment of PEEP, 
mean airway pressure, and other recruitment maneuvers. In 
the present study, PEEP and mean airway pressures did not 
differ between groups. We did not measure FRC and could 
not standardize dynamic compliance for changes in FRC. 
Did we overventilate open lung units? In that regard, we 
checked and reviewed the quantitative change in compli-
ance during the last 20% of inspiration (C
20
) and compared 
this value to the total compliance value for the entire breath 
(C) using the ratio C
20
/C.42 In patients with overdistention, 
the C
20
/C  values decrease below 0.8. Reviewing the same 
in our groups showed that no rabbits were overventilated 
for any significant period of time. However, the 300-minute 
values were significantly lower than the 15-minute values, 
correlating with higher and lower compliance values at 
the corresponding time points, respectively. This corre-
lation suggests that some degree of overventilation was 
taking place that influenced dynamic compliance values 
towards the end of the study. Another factor that has to be 
considered in regard to changes observed in oxygenation 
and shunt over time is lavage-induced pulmonary vascular 
constriction. In addition to surfactant deficiency, large-
volume saline lavage (.20 mL/kg) has previously been 
shown to increase intrapulmonary right-to-left shunt, with 
a simultaneous increase in systolic right ventricular pres-
sure.23 We speculate that a raised systolic right ventricular 
pressure reflects a raised pulmonary vascular resistance, 
which could have adversely affected cardiac output, with 
lowered saturation of mixed venous blood. We substituted 
the true calculation of shunt (which requires measuring 
of mixed venous blood) with the calculated shunt29 whilst 
Table 3 relation between arterial end-tidal PCO2 difference 
and dead-space components
Surfactant  
group
Variable Correlation coefficients
r r2 P
Synsurf VDalv 0.88 0.78 0.0004
VDalv/VT 0.87 0.75 0.0005
VDphys 0.63 0.40 0.0382
VDphys/VT 0.70 0.49 0.0172
Exosurf VDalv 0.74 0.54 0.0096
VDalv/VT 0.19 0.04 0.5788
VDphys 0.51 0.26 0.1071
VDphys/VT 0.35 0.13 0.2861
Exosurf + Ca2+ VDalv 0.90 0.81 0.0002
VDalv/VT 0.93 0.87 0.00003
VDphys 0.74 0.55 0.0091
VDphys/VT 0.81 0.66 0.0024
Abbreviations: VDalv, alveolar dead space; VDalv/VT, alveolar dead space/tidal volume 
ratio; VDphys, physiologic dead space; VDphys/VT, physiologic dead space/tidal volume 
ratio.
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animals were receiving 100% oxygen. Several variables 
may affect this calculation. In this regard, the effect of 
FiO
2
 was taken out of the equation, since FiO
2
 remained 
at 1.0. In regard to possible hypoventilation, we measured 
serial PaCO
2
 levels and attempted to deliver a constant tidal 
volume and minute ventilation throughout the study period. 
Furthermore, PEEP was kept constant, with intermittent 
checks for inadvertent PEEP, and blood pressure and pulse 
rates and rectal temperature did not vary between groups. 
We were able to show that the intrapulmonary right-to-left 
shunt increased from baseline to approximately 45% after 
lavage, thereafter significantly decreasing over time fol-
lowing surfactant instillation. The initial postlavage value 
was very similar to values obtained by Boynton et al35 who 
determined venous admixture and found that the percentage 
venous admixture varied between 35% and 55% at a mean 
airway pressure between 10 and 15 cmH
2
O, respectively. 
We therefore conclude that in the S-treated group, mean 
airway pressure changes possibly altered lung volumes and/
or redistributed ventilation within alveoli already ventilated, 
which affected shunt values.
Since we did not measure pulmonary vascular resistance, 
mixed venous oxygen content, or assessed lung volume, 
we speculate that the decrease in shunt fraction after sur-
factant instillation could be related to one or more of the 
 following: shunting of blood from poorly to better-ventilated 
lung regions (improved ventilation–perfusion matching), a 
decrease in pulmonary vascular resistance (relief of hypoxic 
vasoconstriction) in the open but not hypoventilated com-
partment, or lung-volume recruitment. Similar to our study, 
Wenzel et al25 found that protein-containing bovine surfactant 
replacement after BAL improved gas exchange but failed 
to restore the lung to its prelavage condition, which they 
concluded indicates that exogenous surfactant affects only 
partly the recruitment of the atelectatic areas.
A criticism of the present study is the lack of lung his-
tology, and this would have to be addressed in future stud-
ies involving animal models treated with newer synthetic 
 surfactants. A paucity of studies in this regard, especially 
following surfactant treatment after saline lavage of adult 
rabbits, was noted. Repetitive total lung lavage in adult rab-
bits leads to a reproducible severe surfactant-deficient lung 
injury. The most prominent light-microscopy findings include 
varying degrees of atelectasis, edema, intra-alveolar protein 
leak, hyaline membrane formation, congestion, patchy intra-
alveolar hemorrhage, lymphatic dilatation, and infiltration 
of neutrophils associated with peripheral neutropenia. After 
treatment with surfactant, these changes are still evident, 
albeit more marked in placebo controls.12,43,44 In addition, 
some authors have described better aeration of alveoli, mea-
sured by volume density, in surfactant-treated groups.43
Poly-l-lysine can exist in a variety of conformations, 
depending on the degree of ionization of the amino groups 
in the side chains, temperature, and salt concentration. 
When we examined the circular dichroism spectrum of the 
poly-l-lysine–poly-l-glutamic acid complex, it showed a 
maxima at 218 nm, indicative that the mixture exists in the 
native random-coil conformation (JM van Zyl, unpublished 
results, 2000). This is in accordance with the findings of 
Chittchang et al45 who found that the random coil is the native 
secondary structure of polylysine. Although hydrophobicity 
of poly-l-lysine significantly increases in the order; random 
coil , α-helix , β-sheet conformers,46 we know from our 
previous experience that complexes of poly-l-lysine and 
poly-l-glutamic acid have a degree of hydrophobicity, as we 
have shown that conjugates of polylysine electrostatically 
bind to DNA and make good cell-transfecting agents.47 More-
over, poly-l-lysine adopts a β-sheet conformation from the 
random coil during interaction with  phospholipids.48 On the 
other hand, the random coil (disordered state) of a polymer 
mixture will favor the exposure of the basic charged surface 
groups on the lysine side chains whereby the peptide could 
interact flexibly with other molecules to perform a functional 
role in cell membranes. The overall effect could then pos-
sibly be electrostatic binding to phospholipid monolayers.49 
With regards to SP-B, the α-helical and β-sheet secondary 
structure is proposed to penetrate into the lipid acyl chains 
of the phospholipid membrane lining in alveolar walls, thus 
providing stability and preventing atelectatic collapse.50 We 
therefore make the assumption that the charged amino groups 
of poly-l-lysine in our S preparation could also possibly 
interact with the phospholipid bilayer and thus could mimic 
some structural and/or functional properties of SP-B. On the 
other hand, as positive charges are important for maintaining 
the structure and function of SP-C,51 it can alternatively be 
argued that the overall positive character of poly-l-lysine 
residues in S could then rather contribute to the mimicking 
of SP-C structural and/or functional properties.
To conclude, in keeping with the finding of similar 
experimental and human studies, the best indicator of the 
efficacy of the surfactant was the changes observed in 
systemic oxygenation over time. In addition to this, the 
statistically significant decrease in pulmonary shunt found 
for the S-treated group of animals suggests that the present 
phospholipid mixture formulated with poly-l-lysine–poly-
l-glutamic acid as a complex (cationic and hydrophobic) 
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improves oxygenation in the rabbit model of acute lung 
injury/surfactant depletion.
Disclosure
Johan Smith, Johann van Zyl and Arthur Hawtrey are code-
signers and developers of the peptide-containing synthetic 
surfactant. The surfactant has been patented by InnovUS 
(Stellenbosch University).
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